Cynata Therapeutics Ltd Cash Flow Conversion Efficiency
Cynata Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Cynata Therapeutics Ltd (CYP) has a cash flow conversion efficiency ratio of -0.969x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.79 Million ≈ $-4.10 Million USD) by net assets (AU$5.98 Million ≈ $4.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cynata Therapeutics Ltd (2008–2025)
Cash flow conversion efficiency of Cynata Therapeutics Ltd from 2008 to 2025. This chart illustrates how Cynata Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cynata Therapeutics Ltd (CYP) share price today for real-time trading data and today's change.
Cynata Therapeutics Ltd Cash Flow Conversion Ratio Explained
Cynata Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cynata Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cynata Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see Cynata Therapeutics Ltd (CYP) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crest Nicholson Holdings plc
LSE:CRST
|
-0.142x |
|
Next Mediaworks Limited
NSE:NEXTMEDIA
|
0.009x |
|
Proven Vct PLC
LSE:PVN
|
-0.008x |
|
AFC Energy plc
LSE:AFC
|
-0.349x |
|
AIS Resources Ltd
V:AIS
|
-0.177x |
|
Quinsam Capital Corporation
F:0Q4
|
-0.012x |
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
0.135x |
|
ETHERNITY NETW.(DI) -001
F:82N
|
N/A |
Annual Cash Flow Conversion Efficiency for Cynata Therapeutics Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Cynata Therapeutics Ltd from 2008 to 2025. Review Cynata Therapeutics Ltd (CYP) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.98 Million ≈ $4.23 Million |
AU$-8.72 Million ≈ $-6.17 Million |
-1.458x | -5.63% |
| 2024-06-30 | AU$7.22 Million ≈ $5.11 Million |
AU$-9.96 Million ≈ $-7.05 Million |
-1.380x | -61.69% |
| 2023-06-30 | AU$16.73 Million ≈ $11.84 Million |
AU$-14.28 Million ≈ $-10.11 Million |
-0.854x | -520.04% |
| 2022-06-30 | AU$23.96 Million ≈ $16.95 Million |
AU$-3.30 Million ≈ $-2.33 Million |
-0.138x | +24.35% |
| 2021-06-30 | AU$28.37 Million ≈ $20.08 Million |
AU$-5.16 Million ≈ $-3.65 Million |
-0.182x | +9.81% |
| 2020-06-30 | AU$16.79 Million ≈ $11.88 Million |
AU$-3.39 Million ≈ $-2.40 Million |
-0.202x | +67.25% |
| 2019-06-30 | AU$10.97 Million ≈ $7.76 Million |
AU$-6.76 Million ≈ $-4.78 Million |
-0.616x | -133.37% |
| 2018-06-30 | AU$15.39 Million ≈ $10.89 Million |
AU$-4.06 Million ≈ $-2.87 Million |
-0.264x | +9.59% |
| 2017-06-30 | AU$13.86 Million ≈ $9.81 Million |
AU$-4.05 Million ≈ $-2.86 Million |
-0.292x | +42.44% |
| 2016-06-30 | AU$8.58 Million ≈ $6.07 Million |
AU$-4.35 Million ≈ $-3.08 Million |
-0.507x | -70.56% |
| 2015-06-30 | AU$8.75 Million ≈ $6.19 Million |
AU$-2.60 Million ≈ $-1.84 Million |
-0.297x | -58.11% |
| 2014-06-30 | AU$9.85 Million ≈ $6.97 Million |
AU$-1.85 Million ≈ $-1.31 Million |
-0.188x | +59.64% |
| 2013-06-30 | AU$1.64 Million ≈ $1.16 Million |
AU$-765.76K ≈ $-541.83K |
-0.466x | +45.44% |
| 2012-06-30 | AU$853.75K ≈ $604.08K |
AU$-729.33K ≈ $-516.05K |
-0.854x | +68.73% |
| 2011-06-30 | AU$971.93K ≈ $687.70K |
AU$-2.66 Million ≈ $-1.88 Million |
-2.732x | -30.36% |
| 2010-06-30 | AU$932.00K ≈ $659.45K |
AU$-1.95 Million ≈ $-1.38 Million |
-2.096x | -65.58% |
| 2009-06-30 | AU$961.98K ≈ $680.66K |
AU$-1.22 Million ≈ $-861.47K |
-1.266x | -94.87% |
| 2008-06-30 | AU$2.21 Million ≈ $1.56 Million |
AU$-1.44 Million ≈ $-1.02 Million |
-0.649x | -- |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more